SBIR/STTR Research Award

The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

Award identifier f8d98161c3eb2a3bb53dd4f02f249c9aca43389f5edc592b3878fe7565703d45Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$155,772

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Neogenis Laboratories, Inc.
Proposal award date
2016-09-30
Contract end date
2017-09-29
UEI
Not reported
Solicitation number
PA15-270
Topic code
213

Research abstract

Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more widespread atherosclerosis which may be reducing blood flow to your heart and brain and other parts of the body and not be isolated to just the legs Therefore improving blood flow to the legs in patients with PAD will likely improve blood flow to other organs as well Reduced nitric oxide NO availability or endothelial dysfunction is a hallmark of a number of cardiovascular disorders including PAD L Arginine is the precursor of endothelium derived nitric oxide an endogenous vasodilator L Arginine supplementation improves vascular reactivity and functional capacity in PAD in small short term studies However long term administration of L arginine does not increase nitric oxide synthesis or improve vascular reactivity As opposed to its short term administration long term administration of L arginine is not useful in patients with intermittent claudication and PAD The objective of this application is to determine if restoring NO through an orally disintegrating tablet that releases authentic NO gas can improve blood flow and intermittent claudication in patients with PAD The central hypothesis of this application is that a nitric oxide generating tablet can dilate blood vessels improve blood vascular reactivity and functional capacity in patients with PAD This same technology has already been shown to dilate blood vessels improve vascular reactivity and functional capacity in hypertensive and pre hypertensive patients If successful this non prescription over the counter formulation can provide a safe effective and affordable solution for patients with PAD and perhaps improve long term outcomes in patients with vascular disorders Project Narrative There are approximately million individuals in the US with peripheral artery disease PAD although many are undiagnosed Our poor record in diagnosing these individuals is in part due to insufficient education of the lay public Insufficient nitric oxide NO production is a hallmark of a number of vascular disorders including PAD Restoring NO availability through a nitric oxide generating lozenge may have important therapeutic effects in improving blood flow and functional capacity in patients with PAD A new therapy to improve walking distance in these individuals could improve their quality of life reduce major adverse cardiovascular events MACE by permitting them to increase their physical activity

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.